---
title: "Earlier 3‑Month Viral Load Testing and Longer Visit Intervals After South Africa’s 2023 ART Guidel"
id: "medrxiv-23-uptake-and-outcomes-of-earlier-viral-load-testing-and-longer-visit-intervals-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-uptake-and-outcomes-of-earlier-viral-load-testing-and-longer-visit-intervals-in"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.15.26368143v1?rss=1"
published_at: "2026-11-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Earlier 3‑Month Viral Load Testing and Longer Visit Intervals After South Africa’s 2023 ART Guidel
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-uptake-and-outcomes-of-earlier-viral-load-testing-and-longer-visit-intervals-in
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.15.26368143v1?rss=1)
- **Published At:** 2026-11-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analysed routine electronic medical records from 18 primary clinics across three South African districts for adults initiating or re‑initiating **ART** between January 2022 and March 2025. - The 2023 guideline moved the first scheduled **viral load** (VL) from 6 to 3 months and lowered differentiated care eligibility from 7 to 4 months for virally suppressed clients; the source reported implementation beginning April 2023. - At first VL assessment, 27% had tests in the 3‑month window and 30% in the 6‑month window; 19% were tested outside these windows and 25% had no documented test. - Interrupted time series showed an immediate increase in 3‑month VL testing after implementation, reaching 72–85% coverage by study end, according to the authors. - Assignment to visit intervals ≥6 months among clients with 3‑month suppression rose after the guideline change, reaching 48–71% across districts. - A second VL was documented for 62% of clients who had a first VL in the 3‑ or 6‑month windows; among those, 82% were virally suppressed. - Viral suppression at the first VL did not differ meaningfully between those tested at 3 months (72%) and those tested at 6 months (72%). - Assignment to ≥6‑month visit intervals was not associated with worse subsequent suppression (adjusted RR 1.02, 95% CI 0.99–1.06), per the reported regression analysis. - The authors cautioned that missing VL data limits interpretation and noted incomplete uptake of recommended testing and visit intervals as implementation gaps requiring further evaluation.
## Clinical Analysis & Structured Key Points
Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision | medRxiv Skip to main content Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision View ORCID Profile Elizabeth Kachingwe , View ORCID Profile Mhairi Maskew , View ORCID Profile Nyasha Mutanda , View ORCID Profile Mariet Benade , View ORCID Profile Nancy Scott , View ORCID Profile Allison Morgan , View ORCID Profile Linda Sande , View ORCID Profile Vinolia Ntjikelane , View ORCID Profile Lufuno Malala , View ORCID Profile Musa Manganyane , View ORCID Profile Sydney Rosen doi: https://doi.org/10.64898/2026.11.15.26368143 Elizabeth Kachingwe 1 Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Elizabeth Kachingwe Mhairi Maskew 1 Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mhairi Maskew Nyasha Mutanda 1 Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nyasha Mutanda Mariet Benade 2 School of Public Health, Boston University, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mariet Benade Nancy Scott 2 School of Public Health, Boston University, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nancy Scott Allison Morgan 2 School of Public Health, Boston University, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Allison Morgan Linda Sande 1 Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Linda Sande Vinolia Ntjikelane 1 Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Vinolia Ntjikelane Lufuno Malala 3 National Department of Health, Pretoria, South Africa Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lufuno Malala Musa Manganyane 3 National Department of Health, Pretoria, South Africa Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Musa Manganyane Sydney Rosen 2 School of Public Health, Boston University, Boston, MA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sydney Rosen For correspondence: sbrosen{at}bu.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: South Africas 2023 revised ART Guidelines moved the first scheduled viral load (VL) test from 6 to 3 months after antiretroviral therapy (ART) initiation and accelerated differentiated care eligibility from 7 to 4 months among virally suppressed clients. We assessed uptake of these changes and their association with virologic outcomes. Methods: We analysed routine electronic medical record data from 18 primary healthcare clinics in three South African districts among all adults initiating or re-initiating ART (N=16,338; January 2022-March 2025). Interrupted time series analyses were used to assess uptake of 3-month VL testing and assignment to greater than or equal to 6-month visit intervals following guideline implementation in April 2023. Modified Poisson regression was used to compare relative risks (RRs) for viral suppression at the first and second routine VL tests among clients tested at 3 months (test window=56-111 days) and 6 months (112-<252 days). Results: At the first VL assessment, 27% of participants had VL tests at 3 months and 30% at 6 months; the rest had tests outside either window (19%) or no test documented (25%). Three-month VL testing rose immediately after guideline implementation, reaching 72-85% coverage by the end of the study period. Assignment to greater than or equal to 6month visit intervals among clients with 3-month viral suppression increased after implementation, reaching 48-71% across districts. A second VL result was documented for 62% of clients tested in the 3- or 6-month window. Viral suppression did not differ meaningfully between clients initially tested at 3 months (72%) and those initially tested at 6 months (72%). Among clients with a second scheduled VL result, 82% were virally suppressed. Assignment to greater than or equal to 6-month visit intervals was not associated with subsequent viral suppression (aRR 1.02, 95% CI 0.99-1.06). Results should be interpreted with caution due to missing VL data. Conclusion: South Africas 2023 guideline revision was associated with rapid increases in 3-month VL testing and assignment to longer visit intervals. Viral suppression at the first VL test was similar among clients tested at 3 and 6 months, and longer visit intervals were not associated with poorer outcomes. These findings support earlier differentiation of HIV care within routine service delivery. Incomplete uptake of recommended testing and visit intervals offers opportunities to strengthen implementation and warrants continued evaluation of longer-term outcomes. Competing Interest Statement The authors have declared that no competing interests exist. LM and MM are employees of the government agency that has supervisory authority over the study sites. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The use of de-identified medical record data for this analysis was approved by the Boston University Institutional Review Board (H-38115) and by the University of the Witwatersrand Human Research Ethics Committee (M190445). The protocol was also approved by Provincial Health Research Committees through the National Health Research Database for each study district in South Africa. We received a waiver of informed consent for all medical record data. Authors did not have access to identifying information, as data were provided by the database owner in de-identified format. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability TIER.Net data are owned by the South African National Department of Health. They can be requested from Mr. Mbulelo Cabuko, Director, Health Information Research Monitoring and Evaluation (HIRME) Cluster, National Department of Health, Pretoria, South Africa, Mbulelo.Cabuko{at}health.gov.za. Analytic code for this analysis will be shared on GitHub once the manuscript is published. Funder Information Declared Gates Foundation , INV-031690 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted November 17, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision Elizabeth Kachingwe , Mhairi Maskew , Nyasha Mutanda , Mariet Benade , Nancy Scott , Allison Morgan , Linda Sande , Vinolia Ntjikelane , Lufuno Malala , Musa Manganyane , Sydney Rosen medRxiv 2026.11.15.26368143; doi: https://doi.org/10.64898/2026.11.15.26368143 Share This Article: Copy Citation Tools Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision Elizabeth Kachingwe , Mhairi Maskew , Nyasha Mutanda , Mariet Benade , Nancy Scott , Allison Morgan , Linda Sande , Vinolia Ntjikelane , Lufuno Malala , Musa Manganyane , Sydney Rosen medRxiv 2026.11.15.26368143; doi: https://doi.org/10.64898/2026.11.15.26368143 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (925) Anesthesia (355) Cardiovascular Medicine (5043) Dentistry and Oral Medicine (496) Dermatology (431) Emergency Medicine (681) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1702) Epidemiology (16325) Forensic Medicine (36) Gastroenterology (1245) Genetic and Genomic Medicine (7312) Geriatric Medicine (758) Health Economics (1099) Health Informatics (5327) Health Policy (1479) Health Systems and Quality Improvement (1844) Hematology (600) HIV/AIDS (1386) Infectious Diseases (except HIV/AIDS) (16520) Intensive Care and Critical Care Medicine (1206) Medical Education (702) Medical Ethics (157) Nephrology (755) Neurology (7644) Nursing (380) Nutrition (1138) Obstetrics and Gynecology (1302) Occupational and Environmental Health (1045) Oncology (3758) Ophthalmology (1101) Orthopedics (413) Otolaryngology (470) Pain Medicine (506) Palliative Medicine (144) Pathology (724) Pediatrics (1872) Pharmacology and Therapeutics (758) Primary Care Research (789) Psychiatry and Clinical Psychology (6169) Public and Global Health (10035) Radiology and Imaging (2550) Rehabilitation Medicine and Physical Therapy (1533) Respiratory Medicine (1277) Rheumatology (663) Sexual and Reproductive Health (811) Sports Medicine (601) Surgery (807) Toxicology (109) Transplantation (320) Urology (309)
## Related Clinical Research

- [Methamphetamine reshapes immune cell and plasma signatures in people with HIV](https://medichelpline.com/clinical-feed/medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage.md)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [Barriers and facilitators of oral PrEP uptake and persistence among MSM in Cape Town](https://medichelpline.com/clinical-feed/medrxiv-12-understanding-oral-prep-uptake-and-persistence-among-gay-men-and-other-men-who.md)
- [Nuclear-transport–targeting peptides (SN50 family) as broad anti-inflammatory agents](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-the-nuclear-gateway-a-new-class-of-cell-penetrating-peptides-for.md)
- [HIV Infection Linked to Higher 2‑Year MACE Risk in Chinese Patients with Carotid Atherosclerosis](https://medichelpline.com/clinical-feed/pubmed-42980188.md) (DOI: 10.1080/07853890.2026.2753324)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.